| P50 | author | Andrea Scozzafava | Q28037168 |
| P2093 | author name string | Briganti F | |
| | Supuran CT | |
| P2860 | cites work | The refined 1.9-Å X-ray crystal structure of d-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships | Q27642041 |
| | Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design | Q27734002 |
| | Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes | Q27765257 |
| | Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design | Q28202151 |
| | Structure-based design of a general class of mechanism-based inhibitors of the serine proteinases employing a novel amino acid-derived heterocyclic scaffold | Q36857021 |
| | 28 Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates | Q40112690 |
| | A player of many parts: the spotlight falls on thrombin's structure. | Q40893212 |
| | Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery | Q41398194 |
| | Thrombin inhibitors. 1. Ester derivatives of N alpha-(arylsulfonyl)-L-arginine | Q42272608 |
| | Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position | Q42796622 |
| | Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties | Q43448326 |
| | Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug | Q47293302 |
| | Synthetic low-molecular weight thrombin inhibitors: the ideal antithrombotic drug? An introduction | Q47362443 |
| | Total synthesis of a monocyclic peptide lactone antibiotic, etamycin. | Q54795661 |
| | Carbonic anhydrase inhibitors — Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV | Q58863352 |
| | N-Hydroxysuccinimide Esters in Peptide Synthesis | Q62581050 |
| | Carbonic anhydrase inhibitors. V: Pyrylium salts in the synthesis of isozyme-specific inhibitors | Q67559227 |
| | Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H | Q68790146 |
| | Cyclic amides of N alpha-arylsulfonylaminoacylated 4-amidinophenylalanine--tight binding inhibitors of thrombin | Q71751774 |
| | Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine | Q73707813 |
| | Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis | Q74448345 |
| | Cardiovascular chemotherapy: anticoagulants | Q77297306 |
| P433 | issue | 11 | |
| P304 | page(s) | 939-952 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | European Journal of Medicinal Chemistry | Q3008624 |
| P1476 | title | Protease inhibitors - Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium-sulfanilylguanidine moieties at the P1 site | |
| P478 | volume | 34 | |